What's Happening?
Amgen, a global biotechnology company, has reinforced its commitment to ethical business practices by implementing comprehensive anti-bribery and anti-corruption policies. These policies align with international legislation such as the U.S. Foreign Corrupt
Practices Act (FCPA), which prohibits payments to foreign government officials for business advantages. Amgen's policy defines bribery and corruption as offering or accepting anything of value to influence a person's actions. The company mandates compliance with local laws and requires employees to consult the Law Department for guidance. Amgen's senior leadership spearheads these efforts, providing annual training on relevant laws and conducting risk assessments to support ongoing audits and monitoring activities.
Why It's Important?
Amgen's robust anti-corruption measures are crucial for maintaining its reputation and ensuring compliance with global ethical standards. By adhering to the FCPA and similar international laws, Amgen protects itself from legal and financial risks associated with corruption. These efforts foster trust among stakeholders, including employees, customers, and regulators, and demonstrate a commitment to integrity. The company's proactive approach to training and risk assessment helps prevent unethical practices, thereby safeguarding its operations and enhancing its competitive edge in the global market.
